6-叔丁基-4-亚硝基-O-甲酚 | 7256-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-叔丁基-4-亚硝基-O-甲酚
• 英文名称: 2-tert-Butyl-6-methyl-4-nitroso-phenol
• 英文别名: 6-tert-Butyl-4-nitroso-o-cresol；2-tert-butyl-6-methyl-4-nitrosophenol
• CAS: 7256-05-5
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: OWQGDXJYRASCMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-叔丁基-4-亚硝基-O-甲酚 生成 4-Amino-2-tert-butyl-6-methyl-phenol
  参考文献：
  名称：

  Parc, Revue de l'Institut Francais du Petrole, 1957, vol. 12, p. 304,323

  摘要：

  DOI：
• 作为产物：
  描述：

  2-叔丁基-6-甲基苯酚 在 三乙胺 、 2-methoxyethyl nitrite 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到6-叔丁基-4-亚硝基-O-甲酚
  参考文献：
  名称：

  使用亚硝酸 2-甲氧基乙酯作为 NO 阳离子源的直接芳香亚硝化

  摘要：

  这项工作提出了一种使用亚硝酸 2-甲氧基乙酯 (MOE-ONO) 进行芳族亚硝化的无酸方法。虽然我们小组最初开发的是 NO x自由基源，但我们证明了 MOE-ONO 作为芳香族亲电亚硝化的 NO 阳离子源的实用性。该方法成功地将苯酚、萘酚和其他亲核试剂亚硝化，完全抑制 NO x自由基引起的不需要的硝化。值得注意的是，它能够实现酸敏感底物的亚硝化，这是现有方案难以实现的。

  DOI：

  10.1021/acs.orglett.4c01856

文献信息

• AEROSOLIZED NITRITE AND NITRIC OXIDE - DONATING COMPOUNDS AND USES THEREOF
  申请人：Aires Pharmaceuticals, Inc.

  公开号：EP2237788A2

  公开（公告）日：2010-10-13
• AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF
  申请人：Surber Mark W.

  公开号：US20090196930A1

  公开（公告）日：2009-08-06

  Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.
• AEROSOLIZED NITRITE AND NITRIC OXIDE-DONATING COMPOUNDS AND USES THEREOF
  申请人：AIRES PHARMACEUTICALS, INC.

  公开号：US20130028942A1

  公开（公告）日：2013-01-31

  Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.
• US3944632A
  申请人：——

  公开号：US3944632A

  公开（公告）日：1976-03-16
• [EN] AEROSOLIZED NITRITE AND NITRIC OXIDE - DONATING COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS PERMETTANT D'OBTENIR DU NITRITE ET DE L'OXYDE NITRIQUE AÉROSOLISÉS ET LEURS UTILISATIONS
  申请人：AIRES PHARMACEUTICALS INC

  公开号：WO2009086470A2

  公开（公告）日：2009-07-09

  Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.